Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott’s Lingo Biowearable For Consumers Debuts In The UK As Libre Momentum Continues

Executive Summary

Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.

You may also be interested in...

Are GLP-1 Major Threat To The Insulin Delivery Tech Market?

A small scale study has indicated that GLP-1 agonists could restore normal HbA1c levels in type I diabetics. This therapy could be a huge step forward for the treatment of this chronic disease if this benefit is shown in larger studies.

Dexcom Tries To Close Gap On Abbott in CGM

The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.

Exec Chat: Tandem CEO Sheridan On Coming Mobi Pump, New Algorithms, And Taking Share From Medtronic

In this second of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO John Sheridan provides a tour of Tandem’s next-gen innovations and the competitive landscape.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts